4 completed, 2 active not recruiting, 2 recruiting. 8 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 4, Active not recruiting 2, Recruiting 2 |
| Phase 2 | 1 | Recruiting 1 |
Follow MK-0616: new trials by email Literature Review of MK-0616 trials Research Report on MK-0616
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038) Enlicitide Decanoate, Placebo - Hyperlipidemia, Hypercholesterolemia | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 150 | 2026-10-15 | 2026-11-02 |
| A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037) Enlicitide, Rosuvastatin, Placebo for Enlicitide - Hyperlipidemia | Phase 3 | Completed | Merck Sharp & Dohme LLC | 996 | 2025-11-11 | 2026-11-17 |
| A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029) Enlicitide Decanoate, Placebo - Heterozygous Familial Hypercholesterolemia (HeFH) | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 153 | 2025-08-21 | 2026-11-12 |
| Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension Enlicitide Decanoate - Hypercholesterolemia | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 3000 | 2024-08-05 | 2025-10-07 |
| A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn) Enlicitide, Ezetimibe, Bempedoic Acid - Hypercholesterolemia | Phase 3 | Completed | Merck Sharp & Dohme LLC | 301 | 2024-07-08 | 2026-03-27 |
| Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes Enlicitide Decanoate, Placebo - Arteriosclerosis, Hypercholesterolaemia | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 14550 | 2023-10-09 | 2026-04-23 |
| A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids Enlicitide Decanoate, Placebo - Hypercholesterolemia, Familial Hypercholesterolemia | Phase 3 | Completed | Merck Sharp & Dohme LLC | 2912 | 2023-08-10 | 2026-09-24 |
| A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH) Enlicitide Decanoate, Placebo - Hypercholesterolemia, Familial Hypercholesterolemia | Phase 3 | Completed | Merck Sharp & Dohme LLC | 303 | 2023-08-08 | 2026-02-24 |
Hypercholesterolemia (6) · Hyperlipidemias (2) · Hyperlipoproteinemia Type II (2) · Arteriosclerosis (1)
Spain (7) · United States (7) · Israel (6) · Argentina (5) · Australia (5) · Brazil (5) · Canada (5) · Colombia (5) · New Zealand (5) · Taiwan (5) · United Kingdom (5) · Chile (4) · China (4) · France (4) · Germany (4)
PMID 41206969, PMID 41879224, PMID 42017875
2023 (2)